ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) appointed Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel, effective immediately. Garland succeeds co-founder Corey Goodman, Ph.D., who is stepping down as Chairman and director after more than a decade of scientific and strategic leadership.
The leadership changes occur as ALX Oncology advances evorpacept into late-stage and registration studies and progresses ALX2004 toward critical clinical milestones.
Positive
- None.
Negative
- None.
News Market Reaction – ALXO
In the Jun 30 session, ALXO declined 5.91%, reflecting a notable negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | Conference participation | Neutral | -5.3% | Jefferies healthcare conference fireside chat and webcast announcement. |
| May 08 | Earnings & update | Positive | +11.2% | Q1 2026 results plus pipeline progress and strengthened cash position. |
| May 07 | Clinical data update | Positive | -10.5% | Promising evorpacept plus zanidatamab data in HER2-positive breast cancer. |
| Apr 30 | Conference data preview | Positive | +7.6% | Plan to present CD47 biomarker data and upcoming earnings call. |
| Apr 17 | Inducement grant | Neutral | +4.8% | Large stock option grant to new development and operating officer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions show more divergences than alignments, with several positive updates followed by negative or muted price moves.
Key Terms
registration studies regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Strengthens Leadership with Veteran Executives with Decades of Industry Experience
Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the appointments of Scott Garland as Chairman of the Board of Directors (the "Board") and Michael Listgarten as General Counsel, effective immediately.
Mr. Garland succeeds Corey Goodman, Ph.D., who is stepping down as Chairman and a member of the Board after more than a decade of foundational scientific and strategic leadership. Mr. Garland has served on the ALX Oncology Board since November 2022, where he has consistently leveraged his more than 30 years of biopharmaceutical industry knowledge, including extensive commercial and operational expertise, in support of the Company’s strategic and clinical priorities.
“It has been a privilege to serve as Chairman since co-founding the Company,” said Corey Goodman, Ph.D., Co-Founder and Outgoing Chairman of ALX Oncology. “I am incredibly proud of the progress we have made, particularly advancing evorpacept into late-stage development and progressing ALX2004, both of which have potential of addressing multiple high-need oncology patient populations. Scott is a highly respected leader with a strong track record and I am confident that, under his guidance, the Company will continue to execute at this pivotal stage of growth and deliver long-term value to our stockholders. I look forward to working closely with the Board and management to ensure a seamless transition and continued momentum for the Company.”
“Corey’s contributions to ALX Oncology are immeasurable,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “He helped define our scientific direction and led with unwavering commitment through every stage of the Company’s development. The progress we have made with evorpacept and ALX2004 would not exist without him, and I’m deeply grateful for everything Corey has given to this Company and to the patients we serve. I am equally pleased to welcome Scott as Chairman of our Board. Scott has been an invaluable board member and a trusted partner to our management team. His guidance will be critical as we advance our pipeline and approach critical milestones for both of our programs.”
Commenting on the appointment of Mr. Listgarten to General Counsel, Mr. Lettmann noted, “Michael is a highly accomplished legal leader with a proven track record of guiding biopharmaceutical companies through critical inflection points. His deep domain expertise across complex transactions, governance, and public company matters will be crucial as we advance evorpacept into registration studies, progress ALX2004, deepen our strategic partnerships, and continue executing on our long-term growth strategy.”
About Michael Listgarten
Michael brings over 30 years of combined law firm and in-house experience advising biopharmaceutical companies, with expertise in guiding organizations through the transition from late-stage clinical development to commercialization. Most recently, he served as General Counsel at RAPT Therapeutics, leading the legal and compliance function, supporting complex clinical development programs, regulatory strategy, and capital markets. Prior to that, Michael served as Vice President of Healthcare Law & Chief Compliance Officer at Adamas Pharmaceuticals. Prior to Adamas, he served as Vice President of Healthcare Law at Principia Biopharma. Michael also spent 16 years at Genentech, Inc., where he led a large team of attorneys providing strategic legal and compliance advice to support the development and commercialization of its products. Michael holds a J.D. and Masters of International Affairs from Columbia University, as well as a B.A. in Political Science from the University of Pennsylvania.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (SEC), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact:
Kevin Lui
Director, Investor Relations
kevin.lui@precisionaq.com
Media Contact:
Genevieve Britton
Senior Director, Public Relations
genevieve.britton@precisionaq.com
FAQ
What leadership changes did ALX Oncology (NASDAQ: ALXO) announce on June 30, 2026?
ALX Oncology announced Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel, both effective immediately. According to ALX Oncology, Garland replaces co-founder Corey Goodman, Ph.D., who is stepping down as Chairman and board member after more than a decade of leadership.
Who is Scott Garland and what is his new role at ALX Oncology (ALXO)?
Scott Garland has been appointed Chairman of the Board at ALX Oncology. According to ALX Oncology, he has served on the board since November 2022 and brings more than 30 years of biopharmaceutical commercial and operational experience to help guide the company’s strategic and clinical priorities.
Why is ALX Oncology co-founder Corey Goodman leaving the Chairman role, and will he remain involved?
Corey Goodman, Ph.D., is stepping down as Chairman and board member after over a decade of leadership. According to ALX Oncology, he expressed pride in advancing evorpacept and ALX2004 and plans to work closely with the Board and management to ensure a seamless leadership transition.
Who is Michael Listgarten and what will he do as General Counsel at ALX Oncology (ALXO)?
Michael Listgarten has been named General Counsel for ALX Oncology. According to ALX Oncology, he is described as a highly accomplished legal leader whose expertise in complex transactions, governance, and public company matters will support registration studies for evorpacept, progress of ALX2004, partnerships, and long-term growth strategy.
How do the new leadership appointments impact ALX Oncology’s evorpacept and ALX2004 programs?
The new appointments are intended to support advancement of evorpacept and ALX2004. According to ALX Oncology, Garland’s strategic guidance and Listgarten’s legal expertise will be important as evorpacept moves into registration studies and ALX2004 progresses toward critical milestones and strategic partnerships in oncology.
What development stages are evorpacept and ALX2004 in after ALX Oncology’s June 2026 update?
Evorpacept is being advanced into late-stage and registration studies, while ALX2004 is progressing through development. According to ALX Oncology, these programs target multiple high-need oncology patient populations and are central to the company’s clinical pipeline and upcoming critical milestones.